Abstract
Primary pulmonary hypertension is a rare disease of childhood, which carries a poor prognosis. Patients often present with severe exercise limitation, and untreated life expectancy is less than 1 year. Pharmacological intervention is directed towards reduction of the raised pulmonary artery pressure with vasodilator treatment, initially with calcium antagonists, although more recently long term prostacyclin treatment has shown benefit in some patients. Heart-lung transplantation remains an option for children with severe disease refractory to therapeutic treatment. A 4 year old Bangladeshi girl with dyspnoea, cyanosis, and signs of a low cardiac output, is described. Initial treatment with prostacyclin was gradually reduced, and maintenance treatment with oral sildenafil (Viagra; Pfizer) instituted. At follow up 3 months later, her exercise capacity was greatly improved and she continues to enjoy a good quality of life without obvious side effects. In view of the encouraging initial results, this may become an acceptable adjunct in treating this patient group. Keywords: primary pulmonary hypertension; sildenafil; prostacyclin
Full Text
The Full Text of this article is available as a PDF (80.5 KB).
Figure 1 .
The mechanism of action of sildenafil. cGMP, cyclic guanosine monophosphate; GTP, guanosine triphosphate; GMP, guanosine monophosphate.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Atz A. M., Wessel D. L. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 1999 Jul;91(1):307–310. doi: 10.1097/00000542-199907000-00041. [DOI] [PubMed] [Google Scholar]
- Barst R. J., Maislin G., Fishman A. P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999 Mar 9;99(9):1197–1208. doi: 10.1161/01.cir.99.9.1197. [DOI] [PubMed] [Google Scholar]
- Barst R. J., Rubin L. J., Long W. A., McGoon M. D., Rich S., Badesch D. B., Groves B. M., Tapson V. F., Bourge R. C., Brundage B. H. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 1;334(5):296–301. doi: 10.1056/NEJM199602013340504. [DOI] [PubMed] [Google Scholar]
- Boucek M. M., Novick R. J., Bennett L. E., Fiol B., Keck B. M., Hosenpud J. D. The Registry of the International Society of Heart and Lung Transplantation: first official pediatric report--1997. J Heart Lung Transplant. 1997 Dec;16(12):1189–1206. [PubMed] [Google Scholar]
- Conte J. V., Robbins R. C., Reichenspurner H., Valentine V. G., Theodore J., Reitz B. A. Pediatric heart-lung transplantation: intermediate-term results. J Heart Lung Transplant. 1996 Jul;15(7):692–699. [PubMed] [Google Scholar]
- McLaughlin V. V., Genthner D. E., Panella M. M., Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998 Jan 29;338(5):273–277. doi: 10.1056/NEJM199801293380501. [DOI] [PubMed] [Google Scholar]
- Sanchez L. S., de la Monte S. M., Filippov G., Jones R. C., Zapol W. M., Bloch K. D. Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatr Res. 1998 Feb;43(2):163–168. doi: 10.1203/00006450-199802000-00002. [DOI] [PubMed] [Google Scholar]
- Turko I. V., Ballard S. A., Francis S. H., Corbin J. D. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol Pharmacol. 1999 Jul;56(1):124–130. doi: 10.1124/mol.56.1.124. [DOI] [PubMed] [Google Scholar]